Jason Zuckerbrod is a Partner at Centerview on the healthcare team. He has 15 years of experience advising companies on mergers and acquisitions, shareholder activism, and other complex strategic issues.

Select transactions Mr. Zuckerbrod has advised on include Express Scripts’s sale to Cigna for $67bn, Pfizer’s consumer healthcare joint venture with GSK, Tiffany & Co.’s sale to LVMH for $17bn, Pfizer’s acquisition of Medivation for $14bn, Biohaven’s sale to Pfizer for $12.5bn, Pfizer’s sale of its infant nutrition business to Nestle for $11.9bn, Acceleron’s sale to Merck for $11.5bn, Ventas’s acquisition of Nationwide Health Properties for $7.4bn, Pfizer’s acquisition of Arena for $6.7bn, Pfizer’s acquisition of Anacor for $5.2bn, Merck’s acquisition of Antelliq for €3.3bn, Chinook Therapeutics’s sale to Novartis for up to $3.5bn, Provention Bio’s sale to Sanofi for $2.9bn, DentaQuest’s sale to Sun Life for $2.5bn, Trillium’s sale to Pfizer for $2.3bn, Bellus Health’s sale to GSK for $2.0bn, CinCor Pharma’s sale to AstraZeneca for up to $1.8bn, Perrigo’s sale of its generics business to Altaris for $1.6bn, Chiesi Farmaceutici’s acquisition of Amryt Pharma for up to $1.5bn, Albireo’s sale to Ipsen for up to $1.2bn, VectivBio’s sale to Ironwood for $1.2bn, Gracell Biotech’s sale to AstraZeneca for up to $1.2bn, Inversago Pharma’s sale to Novo Nordisk for up to $1.075bn, Ventas’s spin-off of Care Capital Properties, Anthem’s acquisition of America’s First Choice, Perrigo’s acquisition of Ranir for $750mm, ReViral’s sale to Pfizer for up to $525mm, MiroBio’s sale to Gilead for $405mm, Checkmate’s sale to Regeneron for $250mm, ProPharma Group’s sale to Odyssey, Thirty Madison’s acquisition of Nurx, and Express Scripts’s sale of UBC to Avista Capital.

Prior to joining Centerview, Mr. Zuckerbrod was an analyst at Berenson & Company. He received a B.A., magna cum laude, from Columbia University and lives in Rye, NY with his wife, son, and daughter.